FindTrial
Sign In

Comparing the blood test values In critically infectious patients.

COMPARING THE DIAGNOSTIC ACCURACY OF HISTIDINE RICH GLYCOPROTEIN WITH PROCALCITONIN AS A BIOMARKER OF SEPSIS IN CRITICALLY ILL PATIENTS: A PROSPECTIVE OBSERVATIONAL STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/02/062999
Enrollment
90
Registered
2024-02-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B968- Other specified bacterial agents as the cause of diseases classified elsewhere

Interventions

Intervention1: Nil: Nil

Sponsors

All India Institute of Medical sciences,jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients aged above 18 years 2. Patients having clinical features suggestive of sepsis as defined by Sepsis-3 definition (2016) at the time of ICU admission

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The primary objective is to compare the diagnostic accuracy of histidine rich glycoprotein with procalcitonin for diagnosis of sepsis in Critically Ill patients.Timepoint: Day 0 and at day 7 or day of death or discharge whichever is earlier.—

Secondary

MeasureTime frame
To evaluate the ability of histidine rich glycoprotein to prognosticate the multi organ failure in critically ill sepsis patients as assessed by SOFA scores. To establish histidine rich glycoprotein as a predictor of outcome of sepsis in terms of 28 days mortality. To compare HRG, procalcitonin and c- reactive protein values as a prognostic marker of sepsis.Timepoint: FOLLOW UP FOR 7 DAYS OR TILL THE DATE OF DEATH—

Countries

India

Contacts

Public ContactDR Praveen M V

AIIMS Jodhpur

drnikhilkothari@gmail.com8003996948

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026